Antibodies News and Research

RSS

New finding may aid in development of vaccines against future animal-to-human viral diseases

A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans -; including SARS-CoV-2, the cause of COVID-19 -; may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.

17 Feb 2022

Study reveals mechanisms associated with severe blood clotting in COVID-19 patients

After studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers, including those who work at the National Institutes of Health, identified “rogue antibodies” that correlate with severe illness and may help explain mechanisms associated with severe blood clotting.

17 Feb 2022

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

The present study entailed assessments of both infected and uninfected SOTRs against the D614G-CoV2 baseline virus and eight other variants.

17 Feb 2022

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Researchers recently evaluated the efficacy of the Oxford ChAdOx1 (AZD 1222/ AZD2816) vaccine against the Omicron, Delta, and Beta variants of SARS-CoV-2 in Syrian hamsters.

17 Feb 2022

Vaccination likely to be more protective against SARS-CoV-2 viral variants than natural infection

Antibodies generated by COVID-19 vaccines are more suited to recognizing viral variants than antibodies that arise from natural infection, according to a study by researchers at Stanford Medicine.

17 Feb 2022

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

New study findings reveal that the level of afucosylated anti-spike antibodies increases transiently in infection-naïve individuals after the first COVID-19 vaccine dose.

17 Feb 2022

Fortis Life Sciences Highlights First Year Success

Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced highlights from its first year of operations.

From Fortis Life Sciences 17 Feb 2022

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

Researchers examined the memory B cell repertoire of individuals immunized with three doses of mRNA-based COVID-19 vaccine.

17 Feb 2022

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

Researchers developed a novel computational model to predict the binding affinity between the hACE2 receptor and the RBD of S protein of SARS-CoV-2.

17 Feb 2022

Omicron breakthrough boosts neutralization titers a little more than a 3rd COVID vaccine dose

Researchers compare the neutralizing antibody titers in individuals who received two or three mRNA vaccine doses and experienced breakthrough infections.

16 Feb 2022

Gut enzymes open a gateway to create universal blood-type donor organs

A study published in Science Translational Medicine performed at the Latner Thoracic Surgery Research Laboratories and UHN's Ajmera Transplant Centre has proved that it is possible to convert blood type safely in donor organs intended for transplantation.

16 Feb 2022

SARS-CoV-2 variants are evolving increased infectivity and antibody escape, studies say

First announced by the World Health Organization on Nov. 26, 2021, the SARS-CoV-2 omicron variant spread rapidly around the world, becoming the dominant variant in the U.S. and elsewhere.

16 Feb 2022

Antibodies become more powerful for at least six months after COVID-19 vaccination

For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted against the virus that causes COVID-19, according to a study of the antibody response to the Pfizer-BioNTech vaccine by researchers at Washington University School of Medicine in St. Louis.

16 Feb 2022

New cholera vaccine generates long-lasting antibody responses in mice

Cholera, a diarrheal disease caused by the highly transmissible bacteria Vibrio cholerae, kills tens of thousands of people each year worldwide.

16 Feb 2022

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

A new study examines neutralizing responses to the ancestral variant of SARS-CoV-2, as well as against later variants of concern.

16 Feb 2022

Study confirms that pets can harbor SARS-CoV-2 infection

A new study looks at how dogs and cats within households are susceptible to COVID-19 infection from humans, and whether they act as reservoir species.

16 Feb 2022

Research identifies differences between Omicron lineages BA.1 and BA.2

Researchers recently identified another Omicron lineage, called BA.2, that is more contagious than BA.1, the Omicron lineage that sparked the winter surge of coronavirus cases in January 2022.

16 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

In a new study, researchers examined the effect of electrostatic changes on the ability of the SARS-CoV-2 Omicron variant to escape immunity.

16 Feb 2022

Pregnancy outcomes of pregnant women infected by SARS-CoV-2

A new study evaluated the pregnancy outcomes of pregnant women in the third trimester who were infected by SARS-CoV-2 for the detection of the virus in the placenta and different samples of the newborn as well as detection of antibodies in the cord blood.

16 Feb 2022

Antibodies News and Research

New finding may aid in development of vaccines against future animal-to-human viral diseases

Study reveals mechanisms associated with severe blood clotting in COVID-19 patients

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Vaccination likely to be more protective against SARS-CoV-2 viral variants than natural infection

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

Fortis Life Sciences Highlights First Year Success

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

Omicron breakthrough boosts neutralization titers a little more than a 3rd COVID vaccine dose

Gut enzymes open a gateway to create universal blood-type donor organs

SARS-CoV-2 variants are evolving increased infectivity and antibody escape, studies say

Antibodies become more powerful for at least six months after COVID-19 vaccination

New cholera vaccine generates long-lasting antibody responses in mice

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

Study confirms that pets can harbor SARS-CoV-2 infection

Research identifies differences between Omicron lineages BA.1 and BA.2

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

Pregnancy outcomes of pregnant women infected by SARS-CoV-2

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News